Radiopharmaceutical developer Cellectar has appointed Dr. Bill Clarke as the company's CEO, president, and chief medical officer (CMO).
The Madison, WI-based firm is engaged in the development of phospholipid ether (PLE) platforms as functional, tumor-selective SPECT and PET molecular imaging agents. In addition to these modalities, the firm is seeking to develop its PLE tumor delivery platform to serve as a targeting system capable of treating various cancers.
Clarke was most recently executive vice president, chief technology officer (CTO), and CMO of Chalfont St. Giles, U.K.-based GE Healthcare, according to Cellectar.
By AuntMinnie.com staff writers
April 5, 2007
Related Reading
New growth for diagnostic radiopharmaceuticals, November 9, 2006
Copyright © 2007 AuntMinnie.com